Inventiva at Liver Meeting 2025: Key Presentations on Lanifibranor

Biopharmaceutical company Inventiva, a specialist in the treatment of metabolic steatohepatitis (MASH), has announced its participation in the AASLD Liver Meeting 2025 in Washington, DC, from November 7 to 11. The company will present four abstracts demonstrating the progress of its research on lanifibranor.

Among the topics covered, a phase 3 study, NATiV3, compares the accuracy of digital histological assessments to slide-based histological assessments for liver biopsies. The results suggest significant treatment efficacy, with evidence of fibrosis reversal and therapeutic benefits visible in preclinical rodent models.

In parallel, the integration of biomarkers and digital pathology would allow the development of a promising translational framework, which could strengthen the monitoring and evaluation of future treatments.